GlassScriptPhysician profile
Andrew M Tarr
NPI 1659804607
$2,462.54
in general payments reported to CMS, 2019-2025
23 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $167 · 2024: $959 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.92 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.17 | 2023-2025 | Botox, Qulipta |
| Pfizer INC. | $298.39 | 2023-2025 | |
| Biogen, INC. | $262.08 | 2024-2025 | Tysabri, Vumerity |
| Tg Therapeutics, INC. | $230.72 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $168.49 | 2022-2025 | |
| Emd Serono, INC. | $138.67 | 2023-2025 | Mavenclad |
| Amgen INC. | $81.46 | 2024-2025 | Uplizna |
| Argenx US, INC. | $77.22 | 2024-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $56.47 | 2024 | Ultomiris |
| Celgene Corporation | $56.36 | 2024 | Zeposia |
| Eisai INC. | $54.42 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $53.18 | 2024-2025 | Ponvory |
| Cycle Pharmaceuticals INC | $38.32 | 2025 | Tascenso Odt |
| Lilly USA, LLC | $33.99 | 2024-2025 | Emgality |
| Genentech USA, INC. | $28.38 | 2025 | Ocrevus Zunovo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26.69 | 2024 | Interstim |
| Otsuka America Pharmaceutical, INC. | $25.37 | 2024 | Rexulti |
| Merz Pharmaceuticals, LLC | $21.19 | 2024 | Xeomin |
| Kedrion Biopharma, INC. | $20.14 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Boston Scientific Corporation | $19.86 | 2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2023 | Austedo Xr |
| Bioventus LLC | $15.07 | 2024 | L300 Go System |
| Insightec,INC | $13.90 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Tarr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.